Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies

被引:129
作者
Di Matteo, Vincenzo [1 ]
Di Giovanni, Giuseppe [2 ]
Pierucci, Massimo [1 ]
Esposito, Ennio [1 ]
机构
[1] Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Chieti, Italy
[2] Univ Palermo, Dipartimento Med Sperimentale, Sez Fisiol Umana, I-90134 Palermo, Italy
来源
SEROTONIN-DOPAMINE INTERACTION: EXPERIMENTAL EVIDENCE AND THERAPEUTIC RELEVANCE | 2008年 / 172卷
关键词
5-HT receptors; dopaminergic function; microdialysis; mesocorticolimbic system; nigrostriatal system; antidepressants; antipsychotics; drug addiction;
D O I
10.1016/S0079-6123(08)00902-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this review, the functional interactions between serotonin (5-HT) and dopamine (DA) neuronal systems are discussed with the focus on microdialysis studies in the rodent brain (mainly rats). 5-HT by itself is involved both directly and indirectly via actions on complex neuronal circuitry, in the regulation of DA release through multiple 5-HT receptors, playing a critical role in the development of normal and abnormal behaviours. Recent evidence suggests that dysfunction of dopaminergic and serotoninergic neurotransmitter systems contributes to various disorders including depression, schizophrenia, Parkinson's disease and drug abuse. Here we summarize recent neurochemical works that have extensively explored the role of 5-HT receptors in the control of DA central systems in both basal and drug-induced conditions, using in vivo microdialytic techniques. Several 5-HT receptor subtypes, including the 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3 and 5-HT4 receptors, act to facilitate DA release, while the 5-HT2C receptor mediates an inhibitory effect of 5-HT on DA release. Taken together, neurochemical approaches using microdialysis can not only contribute to clarification of the physiological role of the serotonergic neuronal systems but may also be a powerful pharmacological approach for the development of therapeutic strategies to the treatment of depression, schizophrenia, Parkinson's disease and drug abuse.
引用
收藏
页码:7 / 44
页数:38
相关论文
共 332 条
[1]   Localization of the 5-hydroxytryptamine(2C) receptor protein in human and rat brain using specific antisera [J].
Abramowski, D ;
Rigo, M ;
Duc, D ;
Hoyer, D ;
Staufenbiel, M .
NEUROPHARMACOLOGY, 1995, 34 (12) :1635-1645
[2]   Levodopa - Is toxicity a myth? [J].
Agid, Y .
NEUROLOGY, 1998, 50 (04) :858-863
[3]   Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex [J].
Ago, Y ;
Koyama, Y ;
Baba, A ;
Matsuda, T .
NEUROPHARMACOLOGY, 2003, 45 (08) :1050-1056
[4]   Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex [J].
Ago, Y ;
Nakamura, S ;
Baba, A ;
Matsuda, T .
NEUROPSYCHOPHARMACOLOGY, 2005, 30 (01) :43-51
[5]   THE FUNCTIONAL-ANATOMY OF BASAL GANGLIA DISORDERS [J].
ALBIN, RL ;
YOUNG, AB ;
PENNEY, JB .
TRENDS IN NEUROSCIENCES, 1989, 12 (10) :366-375
[6]   Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission [J].
Alex, K. D. ;
Pehek, E. A. .
PHARMACOLOGY & THERAPEUTICS, 2007, 113 (02) :296-320
[7]   Modulation of dopamine release by striatal 5-HT2C receptors [J].
Alex, KD ;
Yavanian, GJ ;
McFarlane, HG ;
Pluto, CP ;
Pehek, EA .
SYNAPSE, 2005, 55 (04) :242-251
[8]   Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex [J].
Amargós-Bosch, M ;
Artigas, F ;
Adell, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 516 (03) :235-238
[9]   Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex [J].
Amargós-Bosch, M ;
Bortolozzi, A ;
Puig, MV ;
Serrats, J ;
Adell, A ;
Celada, P ;
Toth, M ;
Mengod, G ;
Artigas, F .
CEREBRAL CORTEX, 2004, 14 (03) :281-299
[10]  
ANDERSSON JL, 1995, N-S ARCH PHARMACOL, V352, P374